22nd Century Group Business Summary

22nd Century Group, Inc. (XXII) is a plant biotechnology company primarily generating revenue through the commercialization of its proprietary Very Low Nicotine Content (VLNC) tobacco technology. The company’s business model is structured around two primary segments: Branded Tobacco, featuring its flagship VLN® cigarettes—the only combustible tobacco product authorized by the FDA as a Modified Risk Tobacco Product (MRTP)—and Contract Manufacturing Operations (CMO), which provides private-label manufacturing for third-party tobacco brands. Following the strategic divestiture of its hemp and cannabis operations in 2024, the company has transitioned into a pure-play tobacco harm reduction entity, shifting its focus from high-volume, low-margin CMO contracts toward high-margin branded sales and the licensing of its intellectual property portfolio, which includes over 120 patents. In the competitive landscape, 22nd Century Group operates as a niche disruptor alongside industry giants such as Philip Morris International, British American Tobacco, and Altria Group, distinguishing itself by offering the only FDA-authorized combustible alternative for smokers seeking to reduce nicotine consumption. Originally founded in 1998 by Joseph Pandolfino to leverage nicotine biosynthesis research, the company is currently led by Chairman and CEO Larry Firestone, a turnaround specialist with over 40 years of experience in financial and operational management. The executive team includes CFO Daniel Otto, who brings extensive experience in corporate finance and accounting, and Robert Manfredonia, Executive Vice President of Sales, who oversees the national retail expansion of the VLN® brand. The leadership is supported by a board of directors featuring notable figures such as Lead Independent Director Andrew Arno and Lucille S. Salhany, the former Chairwoman of Fox Broadcasting Company. Recent institutional interest includes a significant stake held by Anson Funds Management LP, reflecting investor focus on the company’s 2026 roadmap toward EBITDA breakeven and its unique regulatory positioning within the evolving FDA nicotine mandate framework.